Currently, various antibodies targeting PD1, PD-L1, PD-L2, and CTLA-4 have shown activity in several cancer other than EOC, such as melanoma [38,39,40,41], lung cancer [42,43,44], head cancer, and renal cell carcinoma [45]. Here, PDCD1 is linked to cancer.